Looking at Effective Treatment Combinations for Advanced Breast Cancer Patients
NCT03424005 · RecruitingThis study is looking at how well different combinations of treatments work for patients with advanced or metastatic breast cancer. It is an umbrella study, meaning it has several groups (or cohorts) of patients who may receive different treatments based on their specific type of breast cancer. The goal is to find effective treatment options for these patients in need.
Locations and contact
This trial is running at 46 locations in 9 countries. 30 of them are currently recruiting.
United States17 locations · 5 recruiting
- Metro-Minnesota Community Oncology Research ConsortiumSaint Paul, MinnesotaRecruiting
- Tennessee Oncology - Chattanooga Oncology & Hematology AssociatesChattanooga, TennesseeRecruiting
- Tennessee Oncology PLLCNashville, TennesseeRecruiting
- The West ClinicGermantown, TennesseeRecruiting
- Vanderbilt University Medical CenterNashville, TennesseeRecruiting
- City of HopeDuarte, CaliforniaCompleted
- H. Lee Moffitt Cancer Center and Research Inst.Tampa, FloridaCompleted
- Hackensack Univ Medical CenterHackensack, New JerseyWithdrawn
- NYU Langone Medical CenterNew York, New YorkWithdrawn
- Regional Cancer Care Associates, LLCHowell Township, New JerseyWithdrawn
- Rocky Mountain Cancer Center - LongmontLongmont, ColoradoCompleted
- Rutgers Cancer Institute of New JerseyNew Brunswick, New JerseyWithdrawn
- Stanford Cancer InstituteStanford, CaliforniaWithdrawn
- Texas Oncology-Plano EastPlano, TexasWithdrawn
- Thomas Jefferson University HospitalPhiladelphia, PennsylvaniaWithdrawn
- University of California San Diego Medical CenterLa Jolla, CaliforniaCompleted
- University of Pittsburgh Medical CenterPittsburgh, PennsylvaniaWithdrawn
Israel7 locations · 7 recruiting
- Assuta Medical CentersTel AvivRecruiting
- Hadassah University Medical CenterJerusalemRecruiting
- Rabin MCPetah TikvaRecruiting
- Rambam Medical CenterHaifaRecruiting
- Shaare Zedek Medical CenterJerusalemRecruiting
- Sheba Medical CenterRamat GanRecruiting
- Tel-Aviv Sourasky Medical CenterTel AvivRecruiting
South Korea5 locations · 5 recruiting
- National Cancer Center Clinical Trials Center / Center for Breast CancerGoyang-siRecruiting
- Samsung Medical CenterSeoulRecruiting
- Seoul National University HospitalSeoulRecruiting
- Severance HospitalSeoulRecruiting
- University of Ulsan College of Medicine - Asan Medical CenterSeoulRecruiting
Spain5 locations · 5 recruiting
- Centro Integral Oncológico Clara Campal Ensayos Clínicos STARTMadridRecruiting
- Hospital del MarBarcelonaRecruiting
- Hospital Universitario Ramon y CajalMadridRecruiting
- Hospital Universitario Virgen MacarenaSeville, SevillaRecruiting
- Vall d?Hebron Institute of Oncology (VHIO), BarcelonaBarcelonaRecruiting
France4 locations · 2 recruiting
- Gustave RoussyVillejuifRecruiting
- Institut Universitaire du Cancer de Toulouse-OncopoleToulouseRecruiting
- Centre Léon BérardLyonActive Not Recruiting
- Institut régional du Cancer MontpellierMontpellierWithdrawn
Australia2 locations · 2 recruiting
- Fiona Stanley Hospital - Medical OncologyMurdoch, Western AustraliaRecruiting
- Peter MacCallum Cancer Centre-East MelbourneMelbourne, VictoriaRecruiting
Germany2 locations · 2 recruiting
- Universitätsklinikum ErlangenErlangenRecruiting
- Universitätsklinikum EssenEssenRecruiting
Taiwan2 locations · 2 recruiting
- National Cheng Kung University HospitalTainanRecruiting
- National Taiwan University HospitalTaipeiRecruiting
United Kingdom2 locations
- Barts Health NHS Trust - St Bartholomew's HospitalLondonCompleted
- Beatson West of Scotland Cancer CentreGlasgowCompleted
Who can join
This study is open to adults aged 18 and older, both men and women. Participants must have advanced breast cancer that cannot be treated with surgery. Some health criteria must be met, and the study team will confirm eligibility before enrolling anyone.
What happens during the trial
Participants will be randomly placed into different treatment groups. Each group will receive a specific combination of treatments until they experience unacceptable side effects or their cancer does not improve. There are various treatment options, including chemotherapy and different targeted therapies.
The trial team
The trial is sponsored by Hoffmann-La Roche with collaboration from Gilead Sciences and Pfizer. The study director is from Hoffmann-La Roche.
Important dates
This trial started on March 30, 2018, and is expected to finish by September 30, 2030. It is currently enrolling new participants.
Additional information
The trial's ID number is NCT03424005. It is a Phase 1/2 trial, meaning it is looking at how well the treatments work and their safety. This study is regulated by the FDA, and it hopes to include about 1,132 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →